Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug

Azeredo da Silveira, Samareh; Shorr, Andrew F.

doi:10.3390/antibiotics9020094

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessConcept Paper

Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug

Samareh Azeredo da Silveira

^1,* and

Andrew F. Shorr

Combioxin SA, 8 rue de la Rôtisserie, 1204 Geneva, Switzerland

Pulmonary and Critical Care Medicine, Medstar Washington Hospital Center, Washington, DC 20010, USA

Author to whom correspondence should be addressed.

Antibiotics 2020, 9(2), 94; https://doi.org/10.3390/antibiotics9020094

Received: 23 January 2020 / Revised: 16 February 2020 / Accepted: 17 February 2020 / Published: 21 February 2020

(This article belongs to the Special Issue Nontraditional Antibiotics—Challenges and Triumphs)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Background: Poor outcomes in severe and resistant infections, together with the economic struggles of companies active in the field of anti-infective development, call for new solutions and front runners with novel approaches. Among “non-traditional” approaches, blocking virulence could be a game changer. Objectives: This review offers a perspective on parameters that have determined the development path of CAL02, a novel anti-virulence agent, with a view to steering clear of the obstacles and limitations that impede market sustainability for new anti-infective drugs. Conclusions and implications of key findings: This case study highlights four pillars that may support the development of other non-traditional drugs and, concurrently, provide a new model that could reshape the field. Therapeutic triggers, study designs, and economic parameters are discussed. View Full-Text

Keywords: severe infections; pneumonia; virulence; broad-spectrum; nontraditional; toxins; endpoint

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

Azeredo da Silveira, S.; Shorr, A.F. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics 2020, 9, 94. https://doi.org/10.3390/antibiotics9020094

AMA Style

Azeredo da Silveira S, Shorr AF. Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug. Antibiotics. 2020; 9(2):94. https://doi.org/10.3390/antibiotics9020094

Chicago/Turabian Style

Azeredo da Silveira, Samareh, and Andrew F. Shorr. 2020. "Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug" Antibiotics 9, no. 2: 94. https://doi.org/10.3390/antibiotics9020094

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Critical Parameters for the Development of Novel Therapies for Severe and Resistant Infections—A Case Study on CAL02, a Non-Traditional Broad-Spectrum Anti-Virulence Drug

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI